SG Americas Securities LLC Purchases New Shares in Twist Bioscience Corporation (NASDAQ:TWST)

SG Americas Securities LLC purchased a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 22,751 shares of the company's stock, valued at approximately $893,000.

Other large investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its stake in Twist Bioscience by 18.5% in the first quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company's stock valued at $251,000 after purchasing an additional 1,006 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Twist Bioscience by 6,499.1% in the first quarter. GAMMA Investing LLC now owns 29,366 shares of the company's stock valued at $1,153,000 after buying an additional 28,921 shares during the period. Vanguard Group Inc. lifted its position in shares of Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after buying an additional 189,791 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Twist Bioscience by 34.5% during the 4th quarter. Wells Fargo & Company MN now owns 37,886 shares of the company's stock valued at $1,761,000 after buying an additional 9,722 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its stake in shares of Twist Bioscience by 18.9% during the 4th quarter. Teacher Retirement System of Texas now owns 17,357 shares of the company's stock worth $807,000 after acquiring an additional 2,755 shares during the period.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 936 shares of Twist Bioscience stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $27,846.00. Following the transaction, the chief financial officer now owns 106,018 shares in the company, valued at approximately $3,154,035.50. The trade was a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Patrick John Finn sold 2,058 shares of the company's stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total transaction of $82,299.42. Following the sale, the chief operating officer now owns 265,460 shares of the company's stock, valued at $10,615,745.40. This represents a 0.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 20,673 shares of company stock valued at $720,412. 3.01% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on TWST shares. Guggenheim reaffirmed a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a report on Tuesday, May 6th. The Goldman Sachs Group cut their price target on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Robert W. Baird cut their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays decreased their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $50.40.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded down $1.25 on Friday, hitting $34.64. 1,488,365 shares of the company traded hands, compared to its average volume of 970,850. Twist Bioscience Corporation has a 12-month low of $27.12 and a 12-month high of $60.90. The company has a current ratio of 4.51, a quick ratio of 4.24 and a debt-to-equity ratio of 0.03. The company has a market cap of $2.08 billion, a P/E ratio of -10.66 and a beta of 2.38. The firm's 50-day simple moving average is $33.73 and its 200 day simple moving average is $41.05.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 54.98% and a negative return on equity of 33.48%. The firm had revenue of $92.79 million for the quarter, compared to analysts' expectations of $92.00 million. Analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.